Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

ation with ChronTech Pharma AB and Transgene S.A. to test the immunogenicity of a DNA/electroporation prime - MVA boost approach against HCV by combining two promising, previously studied clinical candidates. A Phase I clinical study is anticipated to start in Q4 2011.

About Inovio Pharmaceuticals, Inc. Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this re
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... LONDON , July 14, 2014  VirtualScopics, Inc. ... IXI) jointly announced today the formation of a Scientific ... Edward Ashton , Ph.D., chief scientific officer, VirtualScopics, will ... "The formation of this joint Scientific Advisory ... and operational alliance we signed with IXICO plc on ...
(Date:7/13/2014)... 2014 Auf seiner ... veranstalteten F&E-Tagung meldete Astellas Fortschritte ... seines Forschungsrahmenprogramms. Die Tagung bot Astellas die ... klinischen Programme und die Konzernstrategie des Unternehmens ... darin, aktuelle Meldungen zu den Astellas-Initiativen in ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
... Roche NimbleGen (SIX: RO, ROG; Pink Sheets: RHHBY ... genomic services provider Ambry Genetics has officially become a ... EZ Exome workflow. They will provide target-enrichment services ... sequencing services for genetic research. Ambry Genetics has passed ...
... Luminex Corporation (Nasdaq: LMNX ) today announced ... Conference to be held September 20 - 22, 2010, ...   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO ) ... president and chief executive officer, will begin at 8:00 ...
Cached Medicine Technology:Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 2Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome 3Luminex Corporation to Present at UBS Global Life Sciences Conference 2
(Date:7/14/2014)... Carepoint has been designed specifically to ... an intuitive interface for recording, sending, displaying and ... and reporting features. , Hall mc - an ... with Rebecca de Witte to create this exciting ... Carepoint provides seamless, real-time communication between ...
(Date:7/14/2014)... mental activity, and moderate physical activity in middle ... Alzheimer,s disease and dementia in later life, according ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... showed that sleep problems especially when combined ... dementia risk in veterans. Additionally, in a population ...
(Date:7/14/2014)... 2014 Spine Team Texas ... care—from diagnosis to treatment and recovery. Currently all physical ... in or training for certification in The McKenzie Method. ... completed the extensive program. , “We require certification of ... results in better outcomes for spine pain patients,” said ...
(Date:7/14/2014)... 2014 Cadeon Associates Inc. ... into Money,” today announced that it has joined ... that helps partners resell, deploy, and develop solutions ... platform. TIBCO Software Inc. is a global leader ... Spotfire analytics, providing businesses the ability to capture ...
(Date:7/13/2014)... TopDresses100.com, a popular dress company in the global market, ... dresses to its product line. According to the ... guaranteed to be quality made. Now, they are offered ... has a wide variety of elegant dresses for customers ... stock and ready to ship. As an innovation-based supplier, ...
Breaking Medicine News(10 mins):Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2
... (IANS) While the Nepalese government's attention is focused on ... among migrant labourers, intravenous drug users and sex ... groups in the country with the rate of infection ... to Nepal's National Centre for AIDS and STD (sexually ...
... of dengue cases in affluent Singapore has surpassed an epidemic ... . ,The National Environment Agency (NEA) and ... that the weekly number of dengue cases reported last week ... week. This number breached the "epidemic threshold" of 378 cases ...
... exposed themselves outside the Supreme Court on Tuesday in ... legal challenge against advertising restrictions . ,The ... had all raised healthy children on natural breast milk. ... their breasts. ,"Infant formula is dangerous," ...
... John Travolta has blamed psychotropic drugs for the Virginia Tech and ... at the whole story , it has not so much to ... that if you analyze most of the school shootings, it is ... it," New York Post quoted Travolta, as saying. ,The ...
... increasingly monitoring what their kids watch on TV or the ... national survey of 1,008 parents of children ages 2-17, a ... their children's media use, while only 18 percent say that ... concerned about a lot of what they see in the ...
... heat content on interannual-to-decadal time scales much more ... an Indian scientist has revealed. ,Krishna ... Model Diagnosis and Intercomparison (PCMDI), and now at ... find the apparent discrepancies between modelled and observed ...
Cached Medicine News:Health News:Huge Rise in AIDS Cases Among Nepal Housewives 2Health News:Filipino Mothers Go Bare Protesting Against Milk Formula Companies 2Health News:Parents are More Concerned on What Their Kids Watch 2Health News:IIT Delhi Scientist Finds Climate Models Consistent With Ocean Warming Observations 2
... Easy Breeze Air Gel Dryer : Dry up ... 24 gels 8 10 cm without a ... rapid drying, or no heat for controlled drying ... transparent, dried gels. Add and remove gels at ...
Each GelAir™ system drying frame includes two main components, a plastic drying outer frame and a metal square inner frame, as well as 8 clamps per frame. Supplied as a set of two frames....
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
... SGD5040 Slab Gel Dryer incorporates sturdy metal housing and ... The large surface area makes it perfect for drying ... Slim Profile 40cm x 50cm (W x D) ... Rates allows you to optimize your heating ...
Medicine Products: